Новости Америки на русском языке. События и происшествия в Нью-Йорке, Лос-Анджелесе и других городах США.

FDA approves Merck's new hepatitis C pill

U.S. regulators on Thursday approved a new once-daily treatment for the liver-destroying hepatitis C virus made by Merck & Co Inc.

MW-BS443_merck1_20140113121306_MG
Merck officials did not immediately respond to a request for the price of the new drug - marketwatch.com

The Food and Drug Administration approved the drug, Zepatier, with or without the older antiviral drug ribavirin, for patients infected with the most common form of hepatitis C, genotype 1, as well as the less common genotype 4.

Zepatier will compete with drugs that include Gilead Sciences Inc's $94,500-per-treatment Harvoni.

Merck officials did not immediately respond to a request for the price of the new drug.

The Merck drug's FDA label says liver-related blood tests should be performed prior to starting therapy and at certain times during treatment.

Source: foxnews.com

Photo: foxnews.com

FDA approves Merck's new hepatitis C pill обновлено: Январь 29, 2016 автором: Анна Старкова
Нажмите, чтобы поделиться новостью

Текст комментария будет автоматически отправлен после авторизации

Сегодня в новостях

В начало